Paper Details

  1. Home
  2. Paper Details

[Combination of exemestane and everolimus may produce toxic side effects: a new treatment option for metastatic hormone-sensitive breast cancer].

Author: LobbezooDorien J A, SmeetsRuud E H, Tjan-HeijnenVivianne C G, VincentJeroen, de BoerMaaike

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

The combination of exemestane and everolimus is a new treatment option for metastatic hormone-sensitive breast cancer. This article discusses the efficacy and common side effects of this treatment, along with recommendations for their management.
Paper Details　
Original Abstract of the Article :
The combination of exemestane and everolimus is a new treatment option for metastatic hormone-sensitive breast cancer. This treatment is used after progression on non-steroidal aromatase inhibitors. The treatment is generally well tolerated, but sometimes leads to minor or even serious side effects....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/25115205

データ提供：米国国立医学図書館（NLM）

Exemestane and Everolimus: A Double-Edged Sword for Breast Cancer?

Metastatic hormone-sensitive breast cancer, a challenging form of breast cancer, requires effective treatment options. This research explores the combination of exemestane and everolimus as a treatment for this condition. The study investigates the efficacy and safety of this combination, considering the potential side effects and the role of this treatment in the management of metastatic hormone-sensitive breast cancer.

Exemestane and Everolimus: A Powerful Combination, but with Potential Side Effects

The research highlights the effectiveness of the combination of exemestane and everolimus in treating metastatic hormone-sensitive breast cancer. However, it also emphasizes the potential for side effects, including aphthous mouth lesions and pneumonitis. Imagine a desert traveler finding a powerful but unstable oasis – this combination therapy offers potential benefits but also requires careful monitoring and management.

Navigating the Desert of Breast Cancer Treatment: A Cautious Approach

This research underscores the importance of balancing the potential benefits and risks of combination therapies. It emphasizes the need for careful monitoring and management of potential side effects. Just as a desert traveler needs to be aware of potential dangers, clinicians must be vigilant in managing the side effects of this combination therapy.

Dr.Camel's Conclusion

This research on exemestane and everolimus for metastatic hormone-sensitive breast cancer is a reminder that even the most promising solutions can come with unforeseen consequences. It highlights the importance of carefully weighing the benefits and risks of treatment, prioritizing patient safety and ensuring that therapies are tailored to individual needs. Like a desert traveler navigating challenging terrain, clinicians must approach this therapy with caution and vigilance to ensure the best possible outcomes for patients.

Date :
  1. Date Completed 2015-03-30
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

25115205

DOI: Digital Object Identifier

25115205

SNS
PICO Info
in preparation
Languages

Dutch

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.